# A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

> **NCT05213728** · PHASE1 · COMPLETED · sponsor: **Vaxart** · enrollment: 8 (actual)

## Conditions studied

- Norovirus Infections

## Interventions

- **BIOLOGICAL:** VXA-G1.1-NN

## Key facts

- **NCT ID:** NCT05213728
- **Lead sponsor:** Vaxart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-24
- **Primary completion:** 2022-02-01
- **Final completion:** 2022-02-24
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05213728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05213728, "A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05213728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*